Comparative Pharmacology
Head-to-head clinical analysis: FERRIC CITRATE versus PHOSLYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRIC CITRATE versus PHOSLYRA.
FERRIC CITRATE vs PHOSLYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric citrate dissociates to provide ferric iron, which binds dietary phosphate in the gastrointestinal tract, forming insoluble ferric phosphate that is excreted in feces, thereby reducing serum phosphate levels. It also provides iron for erythropoiesis.
Phoslyra (calcium acetate) binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in the feces, thereby reducing serum phosphate levels.
1-2 tablets (210-420 mg elemental iron) orally three times daily with meals.
1330 mg (one caplet) orally three times daily with meals, titrated to achieve serum phosphorus within target range.
None Documented
None Documented
Approximately 6 hours for absorbed iron; clinical effect on serum phosphate occurs within 1–2 weeks.
Not applicable; Phoslyra (calcium acetate) is not absorbed systemically; local effect in GI tract.
Primarily fecal as unabsorbed iron (≥90%); minimal renal excretion (<1%) of absorbed iron.
Renal 100% as unchanged drug, no biliary or fecal elimination.
Category C
Category C
Phosphate Binder
Phosphate Binder